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Successful establishment of a tumour relies on a cascade of interactions
between cancer cells and stromal cells within an evolving microenviron-
ment. Both immune and nonimmune cellular components are key factors
in this process, and the individual players may change their role from
tumour elimination to tumour promotion as the microenvironment devel-
ops. While the tumour–stroma crosstalk present in an established tumour
is well-studied, aspects in the early tumour or premalignant microenviron-
ment have received less attention. This is in part due to the challenges in
studying this process in the clinic or in mouse models. Here, we review the
key anti- and pro-tumour factors in the early microenvironment and dis-
cuss how understanding this process may be exploited in the clinic.
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1. Introduction
The stepwise accumulation of genetic changes from
healthy tissue through to malignancy, is accompanied
by co-option of neighbouring normal cells to support
tumour development and progression. These ‘normal’
cells, which include immune and nonimmune popula-
tions, are collectively termed the stroma. Stromal cells
and cancer cells collectively form the tumour microen-
vironment.
While much work has focused on the characterisa-
tion of oncogenic mutations within epithelial cells from
the point of cancer initiation, the acquisition of muta-
tions alone is not always sufficient to give rise to can-
cer, as the majority of mutagenic cells die or senesce
[1–3]. Indeed, many premalignant lesions already bear
a significant mutational burden; however, only a
minority go on to develop cancer [4–7] and consider-
able lag times from these initial mutations to tumour
development have been reported [8]. This implies a
role for the surrounding stromal environment from the
point of cancer initiation, where non-cell-autonomous
environmental cues provide a niche permissive for
malignant transition.
With our increasing appreciation of the complexities
of the tumour microenvironment, the concept of
exploiting the stroma for therapeutic benefit is becoming
more attractive. Thus, whether the characteristics of an
evolving microenvironment can be exploited towards
early diagnosis and patient stratification approaches in
early stages of carcinogenesis remain- key questions to
be addressed. In this review, we examine the state of our
understanding of components within the microenviron-
ment and their contribution to malignant transition.
While immune components have been the subject of the
most intense research, nonimmune constituents are now
emerging as critical players, and here, we attempt to
emphasise their role, highlighting emerging strategies to
facilitate early detection.
2. Immune cell populations of the
evolving tumour microenvironment:
losing control
The recognition and elimination of genetically distinct
transformed cells by the immune system (immuno-
surveillance) [9] represents a major barrier to the pro-
gression of early cancers. This is evident from
numerous studies reporting a higher incidence of can-
cer in immunocompromised individuals [10–14] and in
mice lacking key cytotoxic components of the immune
systems such as IFN-c, perforin and natural killer cells
(NK cells) [15,16]. The potential of the immune system
to eliminate established tumours in humans has been
well-demonstrated by the effectiveness of immune
checkpoint inhibitors (ICPIs). Therefore, the immune
system’s role in interacting with virtually all nonim-
mune components of the TME as well as mediating
signalling beyond the physical confines of the TME to
the tumour macroenvironment has led to great interest
in the role of the immune system in early tumorigene-
sis [17].
The presence of immune cells in tumours capable of
recognising mutated cancer cells raises several impor-
tant questions, which until now remain a significant
challenge in oncology: How do cancer cells avoid
destruction by the immune system? How is immune
control lost? And when during tumorigenesis is this
control lost?
2.1. Adaptive immunity in malignant
transformation
T lymphocytes are key determinants in tumour fate.
Elevated CD8 infiltration and high CD8:Treg ratios in
established tumours are associated with favourable
long-term prognosis [18–21]. In early lesions experienc-
ing active immune surveillance, tumour neoantigens
generated as a result of genetic instability are pre-
sented on MHC, alerting T cells to the presence of
cancer cells leading to rapid elimination [22–26]. Stud-
ies using carcinogen-driven murine models have shown
that the premalignant microenvironment is signifi-
cantly more immune stimulatory than established
tumour microenvironments, supporting potent T-cell
activation [27,28]. In genetically engineered mouse
models, DuPage et al. [22] elegantly demonstrated
antigen-dependent accumulation of T cells was suffi-
cient to delay malignant lung tumour progression. Pre-
malignant lesions have increased numbers of T cells
compared with fully developed invasive lesions, and
those with lower infiltration exhibit higher incidence of
progression to cancer, indicating a key relationship
between T cells and the epithelium in this stepwise
process [28–33].
However, this is in stark contrast to established
tumours which frequently present with a paucity of
tumour-infiltrating lymphocytes exhibiting an impaired
cytotoxic capacity. Established tumours escape
immune attack through four major mechanisms. First,
mutation of constituents of the antigen presentation
pathway reduces neoantigen presentation rendering
cancer cells ‘invisible’ to T cells. Indeed, 40% of
human non-small-cell lung cancers exhibit defects in
human leucocyte antigens (HLAs), reducing antigen
presentation and promoting immune escape [34].
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Second, functional T cells eliminate immunogenic
clones promoting the development of less heteroge-
neous, less immunogenic tumours in the process, ter-
med immunoediting. In murine sarcoma, antigen-
specific T cells present in early lesions were critical for
immunoediting to permit outgrowth of less immuno-
genic clones [35]. Third, tumours induce a state of dys-
function in infiltrating T cells often termed ‘immune
exhaustion’. DuPage et al. [22] showed that despite an
initially effective T-cell response to delay lung tumour
progression, T cells did not persist and exhibited a
decreased cytotoxicity, despite continued antigen expo-
sure. Indeed, it has been shown that persistent antigen
exposure is a critical trigger for initiation of the T-cell
exhaustion signature [36,37], which is increasingly
appreciated as a graded spectrum of inactivity with its
origins in the early TME. In other models examining
loss of T-cell function in premalignant lesions,
increases in PD-1/PD-L1 expression, Treg diversity and
numbers of circulating Tregs were indicative of T-cell
dysfunction [31,38,39]. Fourth, established tumours
develop an immune-suppressive microenvironment
which protects them from T-cell-mediated immunity.
This has been historically demonstrated by the phe-
nomenon of ‘concomitant immunity’. Tumour forma-
tion is induced in a mouse. Following excision of the
tumour, the same mouse demonstrates immune-medi-
ated resistance to rechallenge with cells from its own
tumour. This is an elegant demonstration that the
immune system may eliminate isolated tumour cells,
but once the microenvironment is formed the tumour
is protected from circulating immunity [40]. Within the
evolving TME, transforming growth factor beta
(TGF-b), epithelial or immune derived, can further
amplify loss of T-cell-mediated immune surveillance
[41,42]. Tregs suppress T-cell effector functions [43,44],
downregulating genes involved in the cytotoxic func-
tion of CD8 T cells including granzyme B and IFN-c,
ultimately tipping the immune balance towards toler-
ance and facilitating immune evasion. TGF-b is key to
the initiation of regulatory programmes and differenti-
ation of CD4 T cells into Tregs [41,45–48]. Interest-
ingly, during malignant transition TGF-b operates in a
context-specific manner, playing opposing roles, ini-
tially functioning as a tumour suppressor capable of
inducing apoptosis in premalignant cells before behav-
ing as a potent immune suppressor, reviewed exten-
sively elsewhere [49–51]. The wider immune functions
of other microenvironment components are discussed
in more detail later in this review. Thus, the perturba-
tion of T-cell functionality in premalignant lesions
does not occur in isolation, but via crosstalk with
other constituents of the immune milieu.
Collectively, these reports add to a growing body of
evidence suggesting that while T cells are essential for
immune control of premalignant lesions, loss of T-cell-
mediated immune surveillance may occur prior to
malignant transition and that immune involvement
actively promotes progression to cancer [31,38,52].
2.2. Innate modulation of the transforming
tumour microenvironment
Although critical fate determinants, T cells do not
operate in isolation, engaging in extensive crosstalk
with other immune cells within the developing
microenvironment [32]. The innate immune system,
comprising neutrophils, NK cells, innate lymphoid
cells (ILCs), dendritic cells (DCs) and macrophages,
functions primarily as a rapid response to pathogens.
In the tumour context, an initially protective response
switches to promote carcinogenesis. While directly con-
tributing to tumorigenesis by selecting immunogenic
clones, the innate immune compartment ultimately
shapes the formation of a tumour microenvironment
providing inflammatory cues capable of controlling T-
cell fate, modulating mutated cancer cells themselves
and modifying underlying tissues.
2.2.1. Macrophages
Of all immune cells, macrophages are the most abun-
dant and display arguably the highest plasticity,
responding rapidly to a diverse array of environmental
stimuli. Activated pro-inflammatory (M1) and anti-in-
flammatory (wound healing, M2) populations have
been described extensively [53,54]. However, in the
context of a tumour, M1 and M2 nomenclatures repre-
sent a grossly oversimplified classification, with macro-
phages existing along a spectrum of phenotypes from
pro- to anti-inflammatory depending on the localised
cues they receive [55–59]. Indeed, reflecting the breadth
of diversity of tumour-derived cues, studies have
described macrophages expressing both markers typi-
cal of M1 and M2 phenotypes, and traits overlapping
with myeloid-derived suppressor cells (MDSCs).
Heterogeneity within the microenvironment of a devel-
oping tumour further amplifies intratumoral macro-
phage diversity and diversity across cancer types.
In very early stages of tumour development,
enhanced numbers of macrophages have been observed
[32,60], and those recruited exhibit a pro-inflammatory
phenotype, activated by host factors such as DAMPs
and tumour cell DNA [24,61,62]. Such infiltrates con-
tribute to immune surveillance and are capable of
directly eliminating immunogenic tumour cell clones
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via release of toxic mediators such as TNF, inter-
leukin-2 (IL-2), reactivate nitrogen and oxygen species
[63–67]. This behaviour is reminiscent of their role in
infection, phagocytosing and presenting tumour-
derived antigen to incoming CD8 T cells [68–72].
Moreover, augmenting these effects, macrophage-
derived IL-1 activates surveilling innate and adaptive
immune cells to inhibit malignant progression. As
occurs for T-cell surveillance, tumours evolve strategies
to evade immune control. Recent work has identified a
mechanism used by neoplastic cells to avoid macro-
phage-mediated immune surveillance during the early
stages of tumorigenesis. Epithelial-derived GDF-15
suppressed macrophage cytotoxic activity by inhibiting
TNF and NO production in an NF-jB-dependent
manner [73]. Therefore, in response to a rapidly adapt-
ing cytokine milieu within developing lesions including
TGF, IL-10, IL-4 and M-CSF, macrophages acquire a
tumour-promoting, immune-suppressive phenotype,
remodelling the microenvironment in the process [74–
77].
However, these antitumour effects of very early
lesions are replaced by a tumour-promoting phenotype
at an early stage of carcinogenesis. This requirement
for macrophages in malignant progression was ele-
gantly demonstrated by Lin et al. who crossed
MMTV-PyMT mice, which develop breast tumours
spontaneously, with osteoporotic (op/op) mice lacking
CSF-1, a cytokine critical for macrophage function.
While they observed little impact on the development
of premalignant lesions, progression to invasive carci-
noma was significantly impaired [76,78].
A key feature of once antitumour, inflammatory
macrophages is the acquisition of immune-suppressive
traits to facilitate malignant progression [60,76,79,80].
To support immune suppression, and thus evasion of
early immune surveillance, macrophages use both
direct and indirect mechanisms. Expression of immune
checkpoints such as PD-L1 inhibits T-cell function,
and release of suppressive cytokines, metabolites and
proteases has far-reaching effects on the immune com-
partment [81,82]. Pro-inflammatory cytokines such as
IL-12 are replaced with the secretion of IL-10 [82,83],
Indoleamine dioxygenase (IDO) [20,84] and TGF-b
[42,49,82,85,86], which together impair T-cell effector
activity [82,87,88] and promote induction of Treg phe-
notypes [47,89]. CCL22 recruits Tregs and along with
CCL5 and CCL17 can inhibit T-cell proliferation
[90,91]. Similarly, IL-10 and TGF-b inhibit DC matu-
ration, reducing antigen-presenting capacity and down-
stream T-cell responses.
Macrophages within the premalignant microenviron-
ment may also elicit tumour-promoting activities
beyond influencing immune cells, either via direct
effects on epithelial cells or by indirect effects on other
nonimmune stromal populations. There are several
direct epithelial mechanisms. First, factors such as
ROS and NOS also induce DNA damage contributing
to genomic instability and mutational burden
[74,75,92–94]. Second, the release of cytokines and
growth factors such as EGF stimulates epithelial pro-
liferation [95–98]. In both chronic inflammation and
Kras-driven models of pancreatic cancer, macrophages
were shown to drive metaplasia of acinar to ductal
cells. Pancreatic acinar cells with oncogenic
KRASG12D upregulated the expression of ICAM-1 to
recruit macrophages, which through matrix metallo-
proteinase-9 (MMP9) and TNF-a production induced
metaplasia, the earliest abnormal pancreatic lesions
[60]. Also in pancreatic cancer, reshaping of the pre-
malignant microenvironment to a PDAC phenotype
has been reported to require early recruitment of
macrophages through CCL9 and CCL2 [99]. Macro-
phage-derived Gas6 has also recently been described as
a critical regulator for the transition between premalig-
nant breast cancer and invasive breast cancer [100].
Signalling via Axl on premalignant epithelial cells,
having engaged with macrophage-derived Gas6,
induced downstream survival signals and concurrent
loss of E-cadherin.
Beyond their direct influence on epithelial cells, as
for any organ, an oxygen supply needs to be estab-
lished to support an expanding epithelial compartment
in hyperplastic lesions [101–103]. Here, macrophages,
including a subset expressing Tie2, contribute to the
angiogenic switch and function as potent inducers of
angiogenesis via production of diverse pro-angiogenic
factors VEGF, TNF-a, IL-8, MMP9 and FGF-2 [104–
109]. These features have been demonstrated in trans-
genic mouse models which recapitulate the very early
neoplastic lesions. In an inducible mouse model of pre-
neoplastic changes in the mammary epithelium, macro-
phage recruitment was necessary for epithelial
proliferation and induction of angiogenesis [110]. Simi-
larly, in mice null for CSF1, delayed progression from
premalignant to invasive lesions was due a failure to
induce angiogenesis by macrophages [78,111], a pro-
cess dependent on MMP9 [112]. This was true also for
intestinal tumorigenesis [113]. Moreover, macrophage-
derived MMP9 plays a pivotal role in tumour angio-
genesis, regulating the bioavailability of VEGF
[114,115].
Macrophages are also involved in remodelling of the
underlying tissues. The extracellular matrix (ECM), a
3D network composed of polysaccharides, proteins
including collagens and glycoproteins, provides
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biochemical and biomechanical cues critical for
tumour progression [116,117]. Macrophages are fre-
quently observed within collagen-rich areas of develop-
ing tumours [118] where they are implicated in the
deposition of matrix [86,119–124], fibril organisation
[119,125–127], cross-linking (stiffening the ECM) and
degradation to release growth factors and support cell
motility [120,128]. Here, they have been shown to
upregulate expression of the matricellular glycopro-
teins, osteopontin, osteoactivin, fibronectin, collagen
types I VI and XIV and secreted protein acidic and
rich in cysteine (SPARC) needed for the assembly and
organisation of collagenous matrix [119,129–131].
Macrophages produce enzymes to modify collagen
assembly such as prolyl 4-hydroxylase a-subunit iso-
form 1 (P4HA1) and procollagen-lysine 2-oxoglutarate
5-dioxygenase 1 and 3 (PLOD-1, PLOD-3) [119], and
modify secreted structure via expression of lysyl oxi-
dase (LOX) and lysyl oxidase-like (LOXL) proteins
[126], supporting matrix stiffening needed for changes
in epithelial morphology (discussed in detail later).
2.2.2. ILCs and NK cells
Within the early cancer setting, ILCs are extremely
efficient at eliminating malignant cells through the
expression of perforin and granzyme, as well as death
ligands, such as TNF-regulated apoptosis-inducing
ligand (TRAIL) and Fas ligand [132–134] ILCs com-
prise the cytotoxic NK cells, and the more recently dis-
covered ‘helper’ ILC subsets. NK cells are key
participants in immune surveillance of early lesions,
‘recognising’ malignant cells by the absence of MHC I
on cancer cells evading cytotoxic T cells [135], and
hence, their presence is associated with good progno-
sis. Evidence supporting this antitumour role came
from studies showing increased cancer incidence in
mice and humans lacking NK cells [136,137], and
increased cancer risk in patients with low NK activity
[138].
A fluctuating balance of activating and inhibitory
receptor–ligand interactions on NK cells controls their
activity. The most interesting of these, from a tumour
immunology perspective, has been the natural killer
group 2, member D (NKG2D) receptor, which can
recognise MHC class I-related proteins A and B
(MICA and MICB), ectopically expressed antigens
such as Rae1 or H60, as well as DNA damage-induced
cell surface ligands [139,140], facilitating tumour cell
elimination [140–142]. Cytokines including IFN-c, IL-
12, IL-18 and IL-15, and the cell surface adhesion
molecule LFA-1 within the TME also potently activate
NK cells [143,144]. Activated NK cells produce TNF,
IFN-c or CSF-2, modulating leucocyte function to
amplify antitumour activity, and also express chemoki-
nes, such as CCL5 and XCL1 to recruit DCs
[145,146]. As the TME establishes, however, NK cells
become much less effective at killing their targets,
exhibiting decreased cytotoxicity and inflammatory
cytokine production. To evade destruction by NK
cells, tumours employ both direct and indirect mecha-
nisms, including coating themselves in collagen and
platelets to shield themselves from NK detection
[147,148]. Cytokines also add to their newly acquired
suppressive phenotype, weakening cytotoxic capacity
and arresting T-cell proliferation [145,149–152].
The role of the other ILC populations is poorly
understood and varies depending on the local microen-
vironment, with both immune-protective and tumour-
promoting effects demonstrated in lung, skin and
colon cancer [153–155]. ILCs are largely tissue-resident
and divided into ILC1, ILC2 and ILC3 subsets func-
tionally corresponding to the TH1, TH2 and TH17
subsets of CD4+ T cells – however this is a consider-
able simplification, and the full nature of these subsets’
functions is still under investigation. Analogous to NK
cells, ILC1s and ILC3s are also activated by IL-15,
and contribute to immune surveillance through the
release of TNF, IL-8 and IL-2, promoting leucocyte
recruitment and proliferation [156,157]. During malig-
nant progression, however, within an increasingly
TGF-b-rich environment, NKs have been reported to
convert into ILC1-like cells with a reduced ability to
control tumour growth [145,149]. ILC3s have also
been shown to drive epithelial proliferation in a IL-22-
dependent manner [158].
Another T-cell population with innate-like proper-
ties are the natural killer T cells (NKTs). These are a
unique population of T cells that recognise lipid anti-
gens presented on the class I-like molecule C1d. ‘Type
I’ NKTs use a semi-invariant TCR made of a specific
alpha chain with a small number of beta chains and
respond in vitro to the lipid alpha Gal-Cer. Mice lack-
ing type I NKTs have generally been found to have
defects in tumour immune surveillance and there is
interest in using alpha Gal-Cer to stimulate antitu-
mour immunity, though results in patients have been
limited. However, in a transgenic model of intestinal
polyps (‘APC min’ mouse), type I NKTs were found
to promote polyp formation by recruitment of Tregs.
‘Type II’ NKTs (or ‘nonclassical’ NKTs) use diverse
alpha and beta TCR chains; in contrast to type I,
mouse experiments suggest they have an immune-regu-
latory, tumour-promoting function. Like the ILCs, the
importance of NKTs in early tumorigenesis is not
well-understood.
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2.2.3. Neutrophils
Neutrophils operate as vital first responders during
infection. Given this critical early role in infection, it
follows that neutrophils also contribute extensively to
early tumorigenesis, with anti- and pro-tumour activi-
ties reported. As for macrophages, this may in part be
a consequence of their functional plasticity. Indeed,
the phenotype of neutrophils in the TME depends on
tumour type and stage. In early tumorigenesis, neu-
trophils are recruited by epithelial- and stroma-derived
chemokines such as G-CSF, CXCL8, CXCL1,
CXCL2, CXCL3 and CXCL5 [159–161]. Here, they
elicit antitumour activity through the release of cyto-
toxic granules, production of TNF-a, NO, H2O2,
TRAIL and IFN-c and expression of costimulatory
molecules [162–164]. At this stage, skewed by IFN-b,
tumour-associated neutrophils (TANs) attract and pro-
mote activation of surveilling T cells [164–166].
However, directly contradicting this antitumour
activity, TANs have also been reported to contribute
to carcinogenesis from the point of tumour initiation.
Local TGF-b pushes neutrophils towards a tumour-
promoting phenotype [166,167], inducing genetic insta-
bility [168] and MAPK-dependent proliferation of pre-
neoplastic cells [169,170] as well as releasing pro-
inflammatory cytokines [97]. In particular, neutrophil-
derived IL-6 and IL-11 have been shown to promote
cancer cell proliferation and inhibit apoptosis via
STAT3 [171]. Now, TANs preferentially recruit Tregs,
directly suppressing CD8 T cells via PD-L1 and indi-
rectly by IL-8-driven arginase production [172–175].
Once established, TANs contribute to shaping of the
microenvironment inducing angiogenesis, remodelling
of ECM through deposition of neutrophil elastase and
MMP release [176–179]. A further feature of neu-
trophils is the production of neutrophil extracellular
traps (NETs). These extracellular DNA structures are
decorated in cytotoxic granules, MMPs and neutrophil
elastase, and although a growing body of evidence
describing roles in tumour circulation [180], metastatic
colonisation [181] and tumour dormancy [182] exists,
their role in early stages of primary tumour develop-
ment remains sparse [183].
2.2.4. Dendritic cells
Dendritic cells are professional antigen-presenting cells
that bridge the innate and adaptive immune compart-
ments, stimulating T cells in an antigen-specific fash-
ion. In the still inflammatory early TME, proficient
DCs effectively present tumour antigen to T cells
alongside costimulatory molecules CD40, CD80 and
CD86, thereby playing a central role in immune
surveillance [67,184–186]. Here, their presence is asso-
ciated with good prognosis [146,184]. However, expo-
sure to suppressive modulators such as VEGF, IL-10,
TGF-b and prostaglandin E2 (PGE2) and microenvi-
ronmental cues such as accumulation of lipids and
decreased pH inhibits DC maturation, decreasing
expression of costimulatory modules and hence reduc-
ing antigen presentation capacity [82,187–190]. This
renders DCs less capable of priming T cells, while
more prone to promote TH2 and Treg responses [191–
193]. PD-L1 expression by DC directly suppresses infil-
trating CD8 T cells [186,194]. Cytokine-induced
changes in transcriptional and metabolic pathways fur-
ther promote a tolerogenic phenotype, stimulating
expression of factors such as IDO, Arg1, iNOS and
STAT3 [195–199]. To further complicate matters, with
reports of anti- and pro-tumour activities depending
on the site examined, our understanding of DCs may
be confounded by tissue specificities in addition to
stage of development [191,200].
Thus, although our knowledge is increasing, the role
of the immune infiltrate in premalignant tissues and
the balance of protection vs. progression remains
unclear (Fig. 1). With a large body of correlative data,
detailed phenotypic and functional analyses are
required. Furthermore, as discussed later in this
review, the choice of model to study the microenviron-
ment in carcinogenesis is critical. Of note, correlations
between inflammation and progression of premalignant
states to cancer are stronger along the gastrointestinal
tract than other sites. These include Barrett’s oesopha-
gus, Crohn’s disease and ulcerative colitis. This raises
the questions of whether different anatomical sites
exhibit different immune infiltration, whether tissue-
specific responses to inflammation exist, and how these
may contribute to progression of precancerous lesions
at different sites. The pro-tumour functions of the
innate immune system in established tumours have
been particularly well-studied, but this in part reflects
the technical challenges of mechanistic studies of very
early lesions.
The mechanisms underlying the transition from
early immune surveillance by innate immune cells to
tumour-promoting phenotypes of macrophages, NK
cells, neutrophils and DCs, later during tumorigenesis,
are poorly understood. This is in part due to the tech-
nical challenges of studying very early lesions in a
‘true’ epithelial setting, which requires transgenic
mouse models. Much of the evidence for early innate
immune surveillance comes from macroscopic observa-
tions of increased cancer rates in immune-suppressed
states, rather than direct observation of the
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premalignant epithelium. One could hypothesise two
key reasons for this shift. According to a cancer cell
centric view, premalignant lesions that acquire the
ability to co-opt pro-tumorigenic innate immunity can
grow into tumours [201,202]. Notably, cancer presents
a paradox to the standard alarm signal sensors of the
immune system: although tumours are genetically dif-
ferent and, thus, capable of promoting antigenic stimu-
lation of T cells, they also release endogenous danger
signals known as damage-associated molecular pat-
terns (DAMPs) to alert the innate immune system.
DAMPs tend to generate an innate response
Fig. 1. Functions of the early tumour microenvironment. Recruitment and activation of cytotoxic CD8 T cells, NK cells, neutrophils and
macrophages result in the elimination of mutated epithelial cells. However, these initial antitumour events driven by immune surveillance
give way to a suppressive environment with tumour-promoting functions. Extensive crosstalk between stromal populations and cancer cells
elicit and amplify pro-tumour functions. These include fibroblast activation and ECM remodelling; induction of the angiogenic switch; release
of growth factors and intermediates to support genomic instability and proliferation; immune exclusion; collaboration between immune cells
to prevent antitumour responses including impaired antigen presentation, reducing cytotoxic capacity; release of suppressive cytokines; and
T-cell deletion/induction of anergy. CD8, cytotoxic T cell; Treg, regulatory T cell; MP1, inflammatory macrophage; MP2, suppressive
macrophage; DC, dendritic cell; NP, neutrophil; NK, natural killer cell.
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compatible with immune regulation, T-cell suppression
and healing. The latter involves the secretion of epithe-
lial growth factors and angiogenic signals which both
support tumour growth. Indeed, tumours have been
famously likened to ‘wounds that do not heal’ [203].
From a wider point of view, this makes sense, as the
innate system has evolved to protect damaged epithe-
lial cells under normal circumstances. Importantly, the
inflammatory insult often precedes the premalignant
transformation. It is well known that chronically
inflamed nonmalignant pathologies such as ulcerative
colitis are at high risk of generating malignant lesions,
because the inflammatory microenvironment provides
an ideal context for premalignant lesions to ‘flourish’
into an invasive cancer [204].
3. Stroma in malignant
transformation: landscaping the
tumour microenvironment
While the interactions between malignant cells and the
immune system play a key role in establishing the
tumour microenvironment during malignant transition,
other components of the host tissue play a critical and
historically overlooked part. Indeed, the accumulation
of stromal components including fibroblasts and ves-
sels is also reported in premalignant lesions including
oesophageal, pancreatic and skin cancers [205–210].
Here, we will briefly discuss emerging roles and our
current understanding of these populations to carcino-
genesis (Fig. 2). Cancer-associated fibroblasts (CAFs)
are one of the most abundant stromal components in
the developing TME and are recognised by numerous
markers such as fibroblast-specific protein 1 (FSP1/
S100A4), vimentin, a-smooth-muscle actin (aSMA),
fibroblast activation protein (FAP), PDGF receptor-a
(PDGFR-a) and podoplanin. CAFs largely originate
as a result of the chronic wound-healing response pre-
sent in the early TME and display a genomic, epige-
nomic and secretomic profile distinct from
untransformed fibroblasts [211–213].
Cancer-associated fibroblasts exhibit diverse pro-tu-
mour functions including growth factor secretion,
angiogenesis, immunoregulation [214–217], ECM
remodelling [218,219] and promoting cancer stemness
[220], invasion [221–223] and chemoresistance
[216,224–227]. To enable such diversity, the CAF com-
partment is highly heterogeneous, composed of multi-
ple subpopulations displaying functional specialisation
from potentially different origins [228–231]. However,
observations of fibroblast accumulation and expansion
around premalignant lesions prior to malignant trans-
formation indicate that, at initial stages, fibroblasts are
predominantly tissue-resident [207,229]. Although the
majority of studies have cited pro-tumour effects of
CAFs, pancreatic cancer studies using the KPC model
have yielded more contradictory results, highlighting
specific roles of CAF subsets. Here, Feig et al. [216]
depleted CAFs based on expression of FAP, reducing
tumour burden. In contrast, studies ablating aSMA
CAFs resulted in poorly differentiated tumours and
shortened survival implying that aSMA-expressing
CAFs, at least in early pancreatic lesions, exhibit
tumour-suppressive activity mediated via immune acti-
vation and physical constraint [232,233]. Together,
with observations of CAF accumulation in early
lesions, these data indicate that the initial fibroblast
response to mutated cells can be tumour-suppressive,
before conversion to a tumour-promoting phenotype
[234,235]. That said, fibroblasts developing with pre-
malignant lesions can significantly influence adjacent
epithelial cells via paracrine signalling [210,220,236–
239]. Fibroblast-derived factors including HGF, IGF,
EGF, TGF-b, IL-6, LIF, oncostatin M, FGF and
metabolites elicit both transformative and proliferative
effects on their targets [236,240–242]. Early in vitro
and xenograft studies in prostate cancer showed that
tumour fibroblasts but not normal counterparts could
stimulate proliferation and transformation of epithelial
cells from benign prostate hyperplasia. Interestingly,
CAFs alone were unable to induce growth of normal
epithelium, providing early indications of a require-
ment for reciprocal communication between the two
compartments for malignant transformation to occur.
Indeed, epithelial cells in precancerous states have been
shown to use TGF-b, PDGF-D and FGF-2 to recruit,
activate and transform tissue-resident fibroblasts
towards a CAF phenotype [234,235]. And, while genet-
ically stable, epigenetic alterations and changes in
expression of noncoding RNA underpin many gene
expression changes following the development of CAF
traits [243–246]. For example, changes in miR-31,
miR-214 and miR-155 facilitate conversion of normal
fibroblasts into CAFs, whereas the upregulation of
miR-21 impacts TGF-b signalling to support acquisi-
tion of a CAF phenotype.
Increasing genomic stress can promote the produc-
tion of activin and TGF-b, supporting CAF activation
[247]. Similarly, the release of ‘danger’ signals such as
IL-1a or DAMPs by epithelial cells is sufficient to pro-
mote CAF activation and upregulation of pro-inflam-
matory genes, with IL-1b for example, released to
promote epithelial proliferation [248–250]. Physical
stresses created in a rapidly changing environment also
support formation and expansion CAFs [218]. For
example, responses to environmental stiffness via
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YAP-TAZ signalling and heat shock factor 1 have
been reported to reprogramme fibroblasts towards a
more tumour-promoting phenotype [251,252]. In
response to epithelial-derived factors, CAFs may pro-
liferate, become ‘activated’ or become senescent [253],
a process which itself can exert significant effects to
adjacent cells via the senescence-associated secretory
phenotype (SASP; reviewed extensively in Ref.
[238,254]).
Cancer-associated fibroblasts exhibit a capacity to
modulate lymphatic vessels, their presence correlating
with lymphatic vessel density and metastasis [255].
Fig. 2. Fibroblast adaptation in the early tumour microenvironment. Within a rapidly changing environment, local cues either biochemical or
biophysical support accumulation and further alterations to an already heterogeneous compartment. With few reports of antitumour activity,
most CAF traits reported across known subsets are pro-tumour. These include release of factors to support cancer cell proliferation and the
angiogenic switch, cytokines to modulate immune recruitment, polarisation, suppression and ECM remodelling. CAF-induced matrix
remodelling operates on multiple levels, binding and releasing cytokine sinks, excluding immune cells and altering functionality, supporting
cell migration and further activating CAFs in a feedforward loop.
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Here, CAF-secreted factors such as hyaluronan [256],
FGF, HGF and VEGF-C directly induce lymphangio-
genesis [257–259], while tumour-derived lysyl oxidase-
like protein 2 (LOXL2) and sonic hedgehog have been
reported to stimulate CAFs to upregulate VEGF-C
and SDF-1a to support lymphatic expansion [260,261].
CAF-derived ECM components such as hyaluronan,
fibronectin, collagen, laminin and osteopontin have
further been identified as lymphangiogenic drivers
[257,262], as have CAF-derived microvesicles which
are reported to exert pro-lymphangiogenic effects via
angiopoietin and Tie2 driving VEGFR3 expression on
lymphatics [263]. Whether similar communications are
established in the early TME to support malignant
transition remains to be determined.
3.1. Crosstalk of CAFs with immune cells
Cancer-associated fibroblasts are emerging as key
immune modulators in the tumour context, with
increasing evidence to suggest that crosstalk between
the nonimmune stroma and leukocytes is essential for
escape from early immune control and tumour pro-
gression [205,214,215,264–266]. CAFs contribute to
initial tumour growth via promotion of an initial local
inflammatory microenvironment through upregulation
of NF-jB-controlled pathways in response to IL-1b
produced by tissue-resident immune cells in the skin
[205]. This gene signature was observed in the preneo-
plastic ‘hyperplastic’ stage, suggesting that early CAF
transformation is critical for both the induction and
maintenance of tumour-promoting inflammation in the
skin. Intriguingly when CAFs from a similar time
point in cervical cancer were examined, no such gene
signature was found, hinting at the importance of the
tissue specificity of both the fibroblastic origin and the
resident immune microenvironment when driving
early-stage tumour progression.
Immune-modulatory fibroblasts within the develop-
ing tumour microenvironment can impact recruitment,
retention and polarisation of the innate immune com-
partment [183,205,249,266–269]. We have shown that
in early stages of cancer, immune-regulatory CAFs
recruit macrophages through a variety of signals
including complement C3, CSF and CXCL12 [269]
and others have shown similar to CXCL12 and
CXCL16, and via the CCL2–CCR2 axis [270–273].
Functioning as potent modulators of macrophage
behaviour [205,265,267,272], fibroblast-derived chiti-
nase-3-like protein 1 (Chi3L1) also drives macrophages
towards a suppressive phenotype in mammary lesions
[266] as does CXCL12 in prostate cancer [270]. Simi-
larly, pancreatic stellate cells (PSCs) isolated from
human pancreatic tumours, but not healthy tissue,
were able to induce an MDSC phenotype in peripheral
blood mononuclear cells (PBMCs) in an IL-6-depen-
dent manner [274]. CAFs also upregulate TLRs,
enabling them to respond to environmental triggers
such as DAMPs and release-soluble mediators that
support both tumour proliferation and immune sup-
pression during tumorigenesis [250,275,276]. This
impact, however, appears to be tissue- and TLR-speci-
fic, with TLR7 and TLR9 instead promoting effective
immune responses required for immune surveillance
[277–279].
Notably, mounting evidence supports a role for
CAFs in modulation of adaptive immune components,
shaping T-cell dysfunction associated with loss of
immune surveillance. The production of soluble factors
such as IL-10 and TGF-b, and metabolic mediators
prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase
(IDO) and arginase can impair activation and cytotox-
icity or push responses towards tumour-promoting
TH2 and TH17 responses [280–283]. FAP-expressing
CAFs can modulate T cells in an NO-dependent man-
ner, their depletion resulting in increased CD8 T-cell
tumour infiltration [215], and podoplanin expressing
CAFs cross-presented tumour antigen in MHC I to
directly induce antigen-specific antigen-dependent T-
cell deletion and anergy via PD-L2 and Fas interac-
tions [214]. Recently, a population expressing MHC II
and CD74 has also been identified implying a similar
capacity to modulate CD4 T cells [217]. However,
indicative that these suppressive behaviours develop as
the microenvironment becomes more established, and
CAFs may initially elicit T-cell stimulatory effects,
reports have also suggested a role for CAF-derived IL-
6-activating T-cell production of IFN-c and IL-17A
[281]. Moreover, CAF-driven recruitment and differen-
tiation of Tregs contribute to the onset of an immune-
suppressive environment [46]. In human breast and
ovarian cancers, subpopulations of CAF were able to
recruit Tregs via CXCL12, mediate retention by
OX40L, PD-L2 and JAM2 interactions and support
survival [284,285]. CAFs also exhibit the capacity to
disrupt NK function either by abolishing production
of cytotoxic granules, granzyme B and perforin by
PGE2 and IDO, or by secretion of MMPs to cleave
NKG2D ligands on target tumour cells [286–288].
While these studies were performed in metastatic
lesions, such behaviours may also apply to the loss of
antitumour activity contributing to immune evasion
during malignant transition.
As alluded to previously, a complex interplay exists
between CAFs and immune cells, the generation of the
tumour microenvironment relies on reciprocal signals.
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For example, while CAFs impact macrophages and
neutrophils, neutrophils also release ROS and NETs
to deliver pro-fibrotic signals [183,289]. Likewise,
CAFs drive macrophage recruitment and polarisation,
yet IL-4-polarised suppressive macrophages induce
expression of the collagen cross-linker enzyme lysyl
hydroxylase 2 in adjacent fibroblasts to promote stiff-
ening of the ECM [281,290].
3.2. CAFs and the extracellular matrix
Following tissue damage, fibroblasts of healthy tissues
rapidly synthesise and deposit ECM as part of the
wound-healing response. In cancer, however, these
mechanisms are perturbed to generate a fibrotic, per-
missive niche [117,123,291]. Here, fibroblasts serve as
the dominant source of ECM and remodelling
enzymes, producing amongst others, collagen family
members, laminins, tenascin C, fibronectin, versican,
hyaluronic acid, lysyl oxidase (LOX) family members
and MMPs [292–296]. The deposition of ECM, even
at very early stages of tumorigenesis, changes the
mechanics of a tissue, contributing to transition from
premalignant disease to cancer [206,297,298]. For
example, in breast cancer, a collagen-dense microenvi-
ronment frequently presenting as high mammographic
density represents a significant risk factor. This was
confirmed when fibroblasts derived from healthy
women with high mammographic density (but no
breast cancer) exhibited significantly higher desmoplas-
tic and pro-tumorigenic phenotypes compared with
counterparts isolated from women with low mammo-
graphic density [117,299,300]. Also in breast cancer,
tissue-resident fibroblasts exposed to local secretion of
granulin increase the expression of a variety of ECM
components [301], promoting the desmoplastic
response and malignant progression of otherwise indo-
lent tumours [302,303]. The increases in ECM reorgan-
isation are catalysed by CAF-derived MMPs and LOX
proteins, which cross-link collagens and mediate fibre
elongation and fibre realignment to promote a stiffer
medium conducive with malignant progression [304–
307]. Importantly, CAF-driven changes to the ECM in
the developing TME do not occur in isolation.
Instead, reciprocal, dynamic communication exists.
Upon remodelling the environment to create a dense,
more rigid matrix, fibroblasts sense the modified
mechanical cues, in turn stimulating production of
cross-linkers LOX to further stiffen the ECM, signal
proliferation, or promote acquisition of a CAF pheno-
type via the SRC-YAP-MYL9/MYL2 axis [218,308].
Thus, within the developing TME, CAFs evolve to
alter cellular, structural and chemical aspects of
tissues, but the physical changes they afford through
deposition and remodelling of the ECM themselves
also play a pivotal role in malignant transition.
3.3. Mechanical cues in the developing tumour
microenvironment
A gradual shift in the rigidity of the ECM from that
of normal tissue is implicated in malignant progression
due to its far-reaching impact on cell morphology,
migration, alignment, angiogenesis and immune
responses [116,123,309–312]. In addition to diverse
paracrine stimuli, epithelial cells respond to physical
stimuli to promote proliferation and morphological
adaptations conducive with acquisition of cancer traits.
The impact of increasing ECM stiffness alone on
epithelial behaviour was elegantly shown by Paszek
et al. in 2005 [309], a concept that was built upon
more recently using methacrylated hyaluronic acid
hydrogels [312]. Here, Ondeck et al dynamically tuned
gels from normal (< 150 Pascals) to malignant
(> 3000 Pascals) stiffness to demonstrate coincident
mechanical sensing and loss of mammary epithelial
morphology through TGF-b and YAP signalling.
Changes in stiffness together with increasingly aligned
fibres promote tumour cell migration, leveraging trac-
tion against remodelled matrix [294,310,313]. Indeed,
the mechanical coupling of ECM with epithelial cells
and CAF cytoskeleton is critical to cell motility in
transforming tissues, with benign and malignant cells
exhibiting very different mechanical properties
[309,314].
Extracellular matrix tethers and immobilises many
soluble mediators, serving as a valuable reservoir for
pro-tumour, CAF-activating and immune-suppressive
factors such as EGF, FGF, PDGF and critically
TGF-b [119,296,315,316]. Many of these provide sub-
tle guidance cues when tethered, but are fully bioactive
once released from proteoglycans upon proteolytic
degradation. Moreover, matrix remodelling and result-
ing increases in stiffness occurring as desmoplasia pro-
gresses in developing tumours can support the
angiogenic switch. This may be a direct consequence
of mechanical compression of vessels driving a hypoxic
response [317–319], through mechanosensing proper-
ties of endothelial cells [320–322], or through MMP-
mediated remodelling via release of matrix-bound fac-
tors such as VEGF, periostin and tenascin C [323].
Disruption of matrix structure, for example inhibition
of modifying enzymes such as LOXL family members
and reduction in cross-linked collagenous ECM
matrix, has been reported to impair both tumorigene-
sis and angiogenesis [324].
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Remodelling of the ECM modulates immune cell
trafficking and functional status [325–327]. This may
occur via direct signals from components of the TME,
but also as a consequence of age. Most cancers arise
in individuals over the age of 60 [328], and in aged tis-
sues, both fibroblasts and immune populations
undergo significant alterations [329–331]. Altered secre-
tomes, and metabolic and ECM profiles have the
potential to combine, propagating pro-tumour dys-
functional states. An increasingly stiff matrix can
induce CAFs to produce chemoattractants such as
CCL2 and CSF-1, attracting innate immune cells,
which may deposit further collagen [119]. This ECM
also serves a source of DAMPs. Proteolytic cleavage
of matrix components such as fibrinogen, fibronectin
domains, versican and decorin creates fragments recog-
nised by TLR2 and TLR4 on immune cells [332–337].
Interactions can promote both differentiation and dys-
function; however, whether such interactions mediate
anti- vs. pro-tumour behaviour remains less clear.
Across melanoma, lung, colon and liver cancers, versi-
can has been reported to drive an immunosuppressive
DC phenotype via TLR2, but has also been reported
to direct DCs into an inflammatory phenotype, critical
for T-cell infiltration and antitumour immunity [338].
The physical properties of remodelled ECM exert
diverse effects on epithelial, stromal and immune cells
it surrounds [116,310,339–343]. The ECM can deter-
mine macrophage shape and polarisation [344], and
collagen-rich matrices bias towards pro-tumorigenic
phenotypes, whereas ECM rich in fibronectin pro-
motes antitumorigenic phenotypes [345–348]. Indeed,
increased deposition of type I collagen has been shown
to directly stimulate inhibitory receptors such as
LAIR-1 on immune cells [349]. Moreover, YAP activa-
tion in cells sensing tensional cues induces the expres-
sion of cytokines to recruit MDSCs and TAMs [350].
A modified ECM, rich in fibrillar collagen, further
contributes to immune suppression by acting as a
physical barrier. T cells are frequently more abundant
within ECM-rich areas surrounding epithelial cells,
and such physical exclusion is associated with poor
prognosis [216,325,351,352]. Stiffer substrates have
been associated with impaired effector function
[353,354]; within dense matrices, T cells are less motile
since migration, which is protease-independent, relies
on a rapid ability to deform and squeeze through
pores and along fibres [355,356]. And while impeded,
they may experience prolonged exposure to immune-
suppressive cytokines.
Beyond any direct effects on cell behaviour within
the developing TME, an accumulation of collagens,
increased cross-linking and stiffening, and rapidly
expanding blood vessels lead to a gradual increase in
interstitial fluid pressure [317,319]. This feature itself
can contribute to transformation of the local environ-
ment. Increases to the movement of fluid through a
tissue, called interstitial flow, are sufficient to drive
changes in fibroblast and collagen fibres towards a
more aligned orientation associated with increasing
stiffness [357,358]. Similarly, fluid movement stimulates
the production of TGF-b by fibroblasts [359] con-
tributing to the alterations in CAF activation status
and ongoing immunosuppressive activity. Interstitial
flow supports the formation of subtle transcellular che-
mokine gradients guiding cells out of physical contact
with the developing tumour and towards draining lym-
phatic vessels, which also sense fluid flux, upregulating
immune-homing chemokines and cell adhesion mole-
cules in the process [360–363]. Such cues are key for
efficient immune trafficking, particularly antigen-pre-
senting cells, to and from the local environment during
tumorigenesis.
A multiplicity of mechanisms exists for CAFs to
influence, and be influenced by, the developing TME.
With growing evidence and technical precision, this is
being ascribed to an increasing number of unique
CAF subpopulations, defined by tissue-specific mark-
ers. This overwhelming complexity can be distilled,
however, into the recurrent functional observations of
these CAFs performing either immune-modulatory,
ECM deposition or mechanical remodelling roles.
Whether these specialised subpopulations are present
from the outset of malignancy as tissue-resident fibrob-
lasts or whether they are plastic and interconvert with
developing cues in the TME remains an open question
in the field.
4. Outreach activities: systemic
effects of the tumour
microenvironment
This review has focussed on the reciprocal microenvi-
ronment changes that facilitate early tumour growth.
However, as practising oncologists are aware, cancer
manifests as a systemic illness. The molecular details
of how cancer ‘reaches out’ to influence whole-body
physiology are beginning to be understood [364,365].
Again, much of the focus has been on immunity. Sys-
temic immunity is impaired in patients with advanced
cancer, and this is clinically relevant with both success
of immunotherapy and mortality from intercurrent
infections [366,367]. Several recent mouse-based studies
have described widespread immune alterations present
in cancer [17,368]. The microenvironment of the
tumour draining lymph node changes in parallel to
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tumour development [269,369], which may impair
onset of immunity or facilitate metastasis. Immune
cytokines may also influence bone marrow function to
release immature myeloid cells which traffic to the
TME to become MDSCs. There has also been interest
in these effects as a prognostic or predictive marker, in
particular the neutrophil:lymphocyte ratio which is
associated with patient outcomes and may be a crude
measure of systemic immune dysfunction [370]. In
addition to the immunological effects, cancer induces
systemic metabolic changes that manifest as cachexia.
Intriguingly, this may be mediated by reciprocal sys-
temic stromal changes: Roberts et al. demonstrated
that the depletion of CAF-like fibroblast populations
from muscle and fat is responsible for loss of mass in
these organs in cancer [371]. There is also overlap
between immune and metabolic reprogramming: the
inflammatory mediators that induce cachexia in turn
elevate immune-suppressive factors such as cortisol,
which further impairs antitumour immunity [372]. It
will be fascinating to see how far these systemic
changes can be traced to early tumour development.
5. Capturing a changing tumour
microenvironment, from mice to
humans
Historical mouse models of cancer often use injectable
human cell lines in immunodeficient mice. While these
models have been key to the progress in developing
cancer treatments for the past half-century, they do
not model the early microenvironment or the adaptive
immune component of the TME. Immune-based treat-
ments are now central to the practice of oncology, and
so, it is essential to use immune-competent models that
reflect the whole TME. Advances over the last decade
in genetic engineering have increased the feasibility of
spontaneous tumour models, which have a neoantigen
profile and local immune infiltrate more representative
of human cases than injectable tumour models [373–
376]. However, 65 million years of evolution have
resulted in a number of significant mechanistic differ-
ences between mice and humans, for example Ly49 vs.
killer immunoglobulin receptor expression on NK cells
[377], differing antibody isotypes [378,379] and differ-
ing transcriptional programmes for B-cell and T-cell
development [378]. There are also genomic differences
between mice and humans that complicate developing
spontaneous models.
Concerted efforts are now being made to ‘humanise’
murine models as far as reasonably possible. Patient-
derived xenografts (PDX) in combination with an
immune system reconstituted from an autologous
haematopoietic stem cell are increasingly used in
tumour immunology, especially to predict patient
response to therapy [380]. However, the injection of
large numbers of late-stage cells to create a viable
xenograft limits their use for the study of the early
TME. Organoid technology meanwhile maintains
many of the advantages of PDX, including maintain-
ing heterogeneity [381] and tumour–stroma interac-
tions [382,383], while also allowing for high-
throughput investigation of the earliest stages of
tumour development. For example, it was shown that
extended TNF-a treatment of human ovarian surface
epithelial cell-derived organoids led to loss of normal
structural organisation and development of an early
cancer legion, thus suggesting a link between a pro-in-
flammatory microenvironment and the initiation of
tumorigenesis [384]. Similarly, a library of human
CRC organoids was created from a range of tumour
stages including normal epithelium up to metastatic
cancer. Sequencing of each organoid highlighted a
high dependency on culture ‘niche factors’ was present
in early organoids, and a subsequent mutational loss
of this requirement was a critical stage in development
into an adenocarcinoma. The authors then went on to
validate this suggestion that transition from early can-
cer to invasive cancer requires increased growth factor
autonomy, xenografting the organoids onto mice [385].
It is becoming increasingly clear therefore that
improved understanding of the early TME will require
utilisation and expansion of both the in vivo and
in vitro toolkit (Table 1).
6. Early detection and therapeutic
intervention
For many cancers, early detection and intervention sig-
nificantly improve survival. In oesophageal cancer, the
detection of the premalignant condition Barrett’s
oesophagus can dramatically increase dismal 5-year
survival rates of less than 20%. However, in the case
of Barrett’s, monitoring by endoscopic surveillance
represents a significant cost and disruption to patients’
lives. Thus, identifying the minority that will go on to
develop OAC is a priority. Examining the underlying
microenvironment may help to define and stratify
patients at greater risk. Indeed, molecular imaging has
been used to exploit changes in tissue glycosylation for
the identification of dysplastic tissues [386–388]. Early
detection of cancers also requires the discovery and
use of robust biomarkers to identify lesions likely to
progress. Thus, strategies to screen at-risk groups in a
minimally invasive fashion are increasingly focusing on
analysis of the premalignant lesion. Although currently
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focused on detecting early changes in the epithelial
compartment [389,390], our increasing understanding
of the complex interactions at play within tissues
undergoing malignant transformation presents the
opportunity to exploit changes within the surrounding
stroma for early detection and patient stratification
(Table 2). Changes in immune content and localisation
[18], ECM characteristics [391–393] and functional
gene signatures [145,394,395] all offer potential.
Indeed, sequencing approaches have enabled large-
scale, single-cell resolution characterisation of the
immune landscape of over 30 different tumour types
[396].
Developing our comprehension of how immune and
fibroblastic components contribute to the transition
from premalignant to cancer affords a range of clinical
approaches for early intervention. Understanding
kinetics of the host responses in malignant transition,
such as loss of immune surveillance, may provide a
unique therapeutic window. Preclinical models have
explored strategies to prevent or reverse the switch in
innate cells to maintain or reinstate an antitumour
phenotype. However, while attractive, many pathways
disrupted during immune suppression are key to main-
tain immune tolerance and protection against autoim-
munity, thus global approaches to inhibit the innate
immune system in early cancer may be counterproduc-
tive. Instead, due to their diverse array of functions,
targeting the fibroblasts may provide an alternative
method to stall malignant transition. While eradication
strategies have been investigated, such an approach
may in practice be hampered by the lack of specific
markers and complexities stemming from heteroge-
neous pro- vs. antitumour subsets [214,216,232,233].
Reprogramming or ‘normalisation’ methods are prov-
ing more attractive. Off the back of studies identifying
novel stromal targets, methods to interfere with CAF
activation status and improve traits such as mechanical
properties via inhibition of factors including FGFR,
hedgehog, NOX, TGF-b, LOX, hyaluronic acid and
all-trans retinoic acid (ATRA) pathways have pro-
gressed from preclinical models to clinical trial. Utili-
sation of re-normalising the TME for enhancement of
existing therapy is well-demonstrated by a recent
report in murine breast cancer. By modifying an
angiotensin blocker to be pH-dependent, the drug was
Table 1. Advantages and limitations of mouse models in the early TME.
Model system Advantages Limitations
Subcutaneous xenograft
(cell line or patient-
derived)
Rapid turnaround of experiments, high
throughput
Human cancer cells
Tractable: genetic manipulation of cell
lines to study pathways accessible
Does not capture organ-specific or early TME
Requires immunocompromised mice
Replacement of stroma by host
Subcutaneous mouse cell
lines
Rapid turnaround of experiments, high
throughput
Tractable: genetic manipulation of cell
lines to study pathways accessible
Intact immune system
Does not capture organ-specific or early TME
Species differences in immunity
Highly transformed cells not representative of early stages or
heterogeneity
Orthotopic injection models Models the organ-specific tumour
microenvironment
If mouse cells used, intact immunity




Models full development of lesions,
including premalignant stages
Intact immune system
Accurate modelling of organ-specific
and early microenvironment
Expensive and time-consuming
Specialised techniques needed for tumour monitoring
‘Clean’ – defined oncogenic drivers decrease mutational spectrum
Mouse genomic differences mean mutating homologs of human
oncogenes does not necessarily produce the same organ cancer
Mouse immune differences may be significant
Timescales of months still do not match the many years of
tumorigenesis in humans
Not available for all cancers yet
Humanised Mouse models Allows study of human cancer-
immune interactions in an animal
system
May overcome species differences in
immunity
Expensive and time-consuming
Transplantation of transformed tissue, which may not reflect early
lesions
Stromal elements are mouse-derived
Marrow transplantation may produce off-target graft vs. host effects
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Table 2. Pro- and antitumour hallmarks of the early TME. SHH, sonic hedgehog; TKI, tyrosine kinase inhibitors.





T cells – cytokines: TNFs, IFN-c, granzyme B, receptors:
FasL, cell contact: perforin, granzyme B.
NKs – cytokines: TNFs, IFN-c, CSF-2, granzyme B,
receptors: NKG2D, KIRs, KKp44, cell contact: perforin.
ILCs – cytokines: TNFs, IL-2, IL-8.
Neutrophils – cytokines: IFNs TNF-⍺, NO, H2O2, receptors:
TRAIL, costimulatory molecules
 ICPI (PD-1/PD-L1, CTLA-4, TIM3, LAG3)
 Vaccines that prevent initial transformation
(HPV)




CAFs – cytokines: TNF-⍺, IL-1b, chemokines: CXCL9,
CXCL10, CXCL11, DAMPs, matrix remodelling.
T cells – cytokines: IFN-g, TNFs.
Macrophages – chemokines: CXCL9, CXCL10, CXCL11,
DAMPs, matrix remodelling.
DCs – chemokines: CCL2, CCL3, CCL17, CCL21, XCL1,
receptors: costimulatory receptors, MHC
 ICPI
 Chemokine modulators (e.g. CXCR4/
CXCL12 axis)
 Engineered DC-based vaccines (Sipuleucel-T)
Promotion of ‘M1’
macrophages
CAFs – cytokines: VEGF, receptors: ICAM-1, chemokines
– CCL2, CCL9, DAMPs.
T cells – cytokines: TNF-⍺, IFN-c, chemokines: NO, ROS,
IL-2, DAMPs.
Macrophages – cytokines: IFN-c, DAMPs.
Neutrophils – cytokines: MIPs, IFN-c, DAMPs
 Myeloid-modulating therapies (TKI/ anti-
VEGF, CD47/SIRPA axis)
 Depletion/repolarisation of M2 macrophages
 Radiotherapy (release DAMPs to promote
innate response)




CAFs – cytokines: TGF-b, IL-1b, IL-6, growth factors: HGF,
IGF, EGF, LIF, oncostatin M, FGF, exosomes, MMPs.
ECM – growth factors: following matrix degradation,
increases in stiffness. mutagens: ROS, NOS.
TAMs – growth factors: TGF-b, EGFs, VEGF, PDGF,
MMPs.
TANs – cytokines: TGF-b, MMPs
ILCs – cytokines: IL-22
 Growth factor inhibitors (e.g. anti-EGFR:
cetuximab)
 TKI (axitinib,regorafenib, lenvatinib)
 ECM modulation – PEGPH20, losartan, sim-
tuzumab, MMP inhibitors, cytokine/ chemo-
kine blocking
Resisting cell death CAFs – cytokines: TGF-b, IL-6, IL-10, IL-11, receptors: PD-
L1, FasL, matrix deposition.
T cells – receptors: reduced TRAIL, FasL.
TAMs – cytokines: IL-6, IL-11, TNF-⍺, matrix deposition.
TANs – cytokines: IL-6, IL-11.




Pro-tumour early functions: impact on stromal cells
Metabolic support of
growing tumour
CAFs – cytokines: TGF-b metabolites: alanine, glutamine,
lactate.
Endothelial cells – angiogenic switch.
TAMs – metabolites: IDO, Arg1, lactate, angiogenic switch
 Metabolite inhibitors
 Vascular ‘normalisation’ (avastin)
 Fibroblast ‘normalisation’
 Reprogramming of TAM
Recruitment of immune-
suppressive cells
CAFs – cytokines: C3, CSF, IL-6, IL-10, TGF-b, GDF-15,
chemokines: CXCL12 and CXCL16.
Endothelial cells – receptors: CLEVER-1.
T cells – conversion to Tregs.
TAMs – conversion to MDSCs, cytokines: IL-6, IL-10 and
TGF-b, chemokines: CCL5, CCL17, CCL22, metabolites:
IDO, arginase.
ILCs – conversion to ILC2 and ILC3
 ICPI
 Neutralising antibodies
 Application of decoy receptors or chemotraps
Impairing T-cell activity CAFs – cytokines: TGF-b and IL-6, metabolites: PGE2 and
IDO, receptors: PD-L1, PD-L2 and FasL, inducing fibrosis.
T cells – cytokines: TGF-b, reduced pro-inflammatory




 Adoptive transfer: TIL therapy, TCR engi-
neered cells and CAR T cells
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active in the more acidic microenvironment of a devel-
oping tumour but not in normal neutral pH tissue.
Therefore, only CAFs in the TME were reprogrammed
to a normalised state, and not activated fibroblasts in
adjacent tissue. This normalisation enhanced the effi-
cacy of ICPI. Likewise, the repurposing of existing
agents shown to have effects on stroma and wider
TME is under trial [397–400]. For example, in PDAC,
the drug ATRA (which is widely used to treat acute
promyelocytic leukaemia) was shown to restore pan-
creatic stellate cells to a quiescent state only seen in
the very early stages of tumour initiation, and these
treated cells displayed significantly decreased pro-tu-
mour functions. However, the ability of mouse models
to predict therapeutic effect is not straightforward.
Preclinical models suggest that hedgehog inhibitors
may be useful for the treatment of pancreatic cancer
by restricting stromal growth and improving drug pen-
etration [401]. However, subsequent clinical trials have
been disappointing [402]. Further preclinical studies
have shown that while hedgehog inhibition reduces
desmoplasia, it can also enhance epithelial growth.
The unpredictable balance of these factors in humans
may then determine whether the treatment has a posi-
tive or negative effect [403].
Beyond the design of novel therapeutic targets, a
thorough understanding of the composition and roles
of stroma of the early tumour microenvironment may
inform patient prognosis or predict response to treat-
ment [404–406]. For example, a stromal gene signature
has been shown to predict poor survival and metasta-
sis in high-grade serous ovarian cancer. In summary,
although the early stroma offers many opportunities
for intervention for patient benefit, key barriers to
advancing this are the early detection of these lesions,
and a more thorough understanding of the relationship
between animal models and different human tumours
at early stages of development.
7. Perspectives and conclusions
Tissues surrounding mutated cells play a pivotal role in
carcinogenesis, from initial elimination responses
through to supporting growth and development of a per-
missive niche. Recent technological advances have dra-
matically increased our appreciation of the complex
networks at play, the duality of our immune system, the
increasing diversity and functional specialisation of
fibroblasts, and the impact of changing tissue mechanics.
Even so, outstanding challenges remain. We know rela-
tively little about the plasticity, heterogeneity and inter-
dependencies that define the evolving stromal landscape.
Nevertheless, it is likely that these complex tumour–
stroma interactions compliment the well-documented
tumour heterogeneity and cumulatively contribute to
increased robustness of early tumours [407], and we now
face the challenge of dissecting these roles, addressing
impact of tissue specificities and previously overlooked
traits such as the ageing microenvironment. A better
understanding facilitated by the development mouse
models that more faithfully recapitulate early stages of
cancer, the installation of extensive patient sample
repositories and inclusion of stromal parameters in trials
will help to unravel underpinning mechanisms in real
time, and most importantly stand to inform new
approaches to better identify and treat patients early.
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Table 2. (Continued).
Function Stromal mechanism Therapeutic strategies
Macrophages – cytokines: IL-10, chemokines: CCL22,
metabolites: IDO, Arg1, lactate, receptors: PD-L1, inducing
fibrosis.
DCs – cytokines: TGF-b, IL-10, metabolites: IDO, Arg1
receptors: PD-L1, PD-L2, reduced costimulation.
ILCs – cytokines: IL-12, IL-22, receptors: NKp46
 Immune-stimulatory treatments (STING
pathway)
Fibroblast function Fibroblasts – cytokines: TGF-b, IL-1a, growth factors:
PDGF-2,FGF-2, microRNA
ECM – increases in stiffness, signalling: YAP-TAZ, HSF-1
T cells – cytokines: IL-1, IL-6 and TNF.
TAMs – cytokines: TGF-b, IL-6, growth factors: PDGFs,
FGF2, mutagen: ROS
 Prevent CAF activation (SHH inhibitor sari-
degib, galunisertib)
 CAF action (AMD3100)
 CAF ‘normalisation’ (ATRA, paricalcitol)
 Destabilisation of ECM
 Reprogramming of TAM
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